Economic implications of biological therapies for Crohn's disease: Review of infliximab

PharmacoEconomics

Volumn 23, Issue 9, 2005, Pages 875-888

  Bodger, Keith ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHIMERIC ANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE;

CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; CROHN DISEASE; DECISION MAKING; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECONOMIC EVALUATION; FISTULA; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; MEDICAL RECORD; MEDLINE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TEACHING HOSPITAL;

ANTIBODIES, MONOCLONAL; BIOMEDICAL TECHNOLOGY; CLINICAL TRIALS; CROHN DISEASE; DRUG COSTS; DRUG RESISTANCE; HUMANS; PEER REVIEW;

EID: 24944514548     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523090-00002     Document Type: Review

References (50)

1. Ward FM, Bodger K, Daly MJ, et al. Clinical economics review: medical management of inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 15-25
2. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3: 81-92
3. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35
4. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706
5. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57
6. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease: based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146-50
7. Bebb JR, Scott BB. How effective are the usual treatments for Crohn's disease? Aliment Pharmacol Ther 2004; 20: 151-9
8. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mer-captopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-9
9. Bell SJ, Kamm MA. Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease. Aliment Pharmacol Ther 2000; 14: 501-14
10. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16: 144-50
11. Louis E, Peeters M, Franchimont D, et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clin Exp Immunol 2000; 119: 64-8
12. Negoro K, Kinouchi Y, Hiwatashi N, et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 1999; 117: 1062-8
13. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35
14. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405
15. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9
16. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85
17. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9
18. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13
19. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610
20. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002; 20: 639-52
21. Feagan BG. Review article: economic issues in Crohn's disease: assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther 1999; 13 Suppl. 4: 29-37
22. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000; 95: 524-30
23. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000; 95: 1955-60
24. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14: 318-27
25. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14: 309-17
26. Bassi A, Dodd S, Williamson P, et al. Cost-of-illness of inflammatory bowel disease in the United Kingdom: a single-centre retrospective study. Gut 2004; 53 (10): 1471-8
27. Monthly Index of Mechanical Specialities (MIMS). London: Haymarket Medical Publications Ltd., 2004
28. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000; 95: 677-83
29. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004; 99: 91-6
30. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002; 35: 151-6
31. Jewell DP, Probert CSJ, Lobo AJ, et al. The effect on health care resources of infliximab use in Crohn's disease [abstract]. Gastroenterology 2004; 126 (4 Suppl. 2): S1218
32. National Institute for Clinical Excellence. Full guidance on the use of infliximab for Crohn's disease (Technology Appraisal Guidance No. 40), 2002 [online]. Available from URL: http://www.nice.org.uk/page.aspx?0=31337 [Accessed 2005 Jan 1]
33. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003; 7: 1-67
34. Marshall JK, Blackhouse G, Goeree R, et al. Clinical and economic assessment: infliximab for the treatment of Crohn's disease. Technology Overview No. 8. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2002
35. Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001; 120: 1640-56
36. Jaisson-Hot I, Flourie B, Descos L, et al. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004; 20 (3): 274-9
37. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997; 3: 265-76
38. Hilsden R. Funding the new biologics: what can we learn from infliximab? The CCOHTA report: a gastroenterologist's view-point. Can J Gastroenterol 2002; 16: 865-8
39. Lewis S. Funding the new biologics: public policy issues in drug formulary decision making. Can J Gastroenterol 2002; 16: 869-72
40. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31
41. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13 Suppl. 4: 16-22
42. Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000; 14 Suppl. C: 29C-32C
43. Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth J Med 2003; 61: 111-9
44. Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999; 117: 1433-7
45. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8
46. Lyseng-Williamson KA, Foster RH. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004; 22: 107-32
47. Mitton CR. A health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease. Can J Gastroenterol 2002; 16: 873-6
48. Cohen RD. IBD indirect costs: the sleeping giant? Gastroenterology 2003; 125: 982-4
49. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002; 8: 237-43
50. Bassi A, Dodd S, Williamson P, et al. Health state utilities and willingness-to-pay in inflammatory bowel disease: a study of feasibility and validity [abstract]. Aliment Pharmacol Ther 2005; 21: 197